Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2710752 | 0.94 | DPP4 (0.47) | RAB9AMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL2710450 | 0.88 | NPC1 (0.49) | RAB9AMAPTSMN1; SMN2DPP4NPC1 | |
| SCHEMBL2710588 | 0.88 | DPP4 (0.48) | RAB9AMAPTSMN1; SMN2DPP4NPC1 | |
| SCHEMBL2709289 | 0.88 | MAPT (0.51) | RAB9AMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2709994 | 0.87 | DPP4 (0.46) | RAB9AMAPTDPP4NPC1DPP8 | |
| SCHEMBL2707234 | 0.87 | DPP4 (0.60) | RAB9AMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2711735 | 0.86 | DPP4 (0.46) | RAB9AMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2711530 | 0.86 | DPP4 (0.56) | RAB9AMAPTDPP4NPC1DPP8 | |
| SCHEMBL2708531 | 0.85 | DPP4 (0.49) | MAPTALDH1A1SMN1; SMN2DPP4DPP8 | |
| SCHEMBL2709697 | 0.84 | DPP4 (0.59) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | RAB9A 3301/4885MAPT 3343/4885ALDH1A1 229/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | RAB9A 3301/4885MAPT 3343/4885ALDH1A1 229/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | RAB9A 3567/4885MAPT 3585/4885ALDH1A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.